B
Beijing Puyi Biotechnology
High-throughput, long-read nanopore gene sequencing systems.
About Beijing Puyi Biotechnology
Beijing Puyi Biotechnology Co., Ltd. (Polyseq) is a life sciences company focused on the development and commercialization of nanopore-based gene sequencing systems. The company leverages proprietary technology to produce high-accuracy, high-throughput, long-read, and low-cost nanopore sequencers, along with the necessary reagents and consumables. The firm's product portfolio is built upon a proprietary sequencing chemistry system, which is based on independently resolved atomic-scale structures of novel biological nanopores and integrated with nucleic acid chemistry and protein engineering. This is combined with integrated circuit chips, software engineering, and deep learning algorithms to create a high-performance sequencing platform.
Polyseq offers a range of products including various nanopore sequencers like the PolyseqOne, PolyseqHive, and PolyseqX2, which offer different throughput capabilities. For example, the PolyseqX2 is designed for high-throughput applications with a capacity of up to 800 GB and can achieve megabase-level ultra-long read lengths. The company also provides sequencing chips, such as the PolyseqCell and PolyseqXCell, and a variety of test kits for library preparation. A key feature of their technology is the reusable and cleanable chip design, which aims to significantly reduce sequencing costs. Their C2.0 Sequencing Chemistry System is designed to provide consistent 99% accuracy across various applications by using a novel nanopore protein and speed-control protein.
The company's technology has a wide array of applications across multiple sectors. These include research sequencing, pathogen detection, genetic disease testing, tumor detection, forensic identification, reproductive health, pharmaceutical quality control, public health and epidemic prevention, and customs inspection. For instance, in pathogen detection, the technology allows for rapid and accurate identification to guide clinical treatment. In March 2026, the company announced it had raised CNY 150 million in a funding round that included investors such as IDG Capital and CAS Venture Capital Management.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- 1
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Genetics and genomics, Health Diagnostics, Biotech and Pharma, Techbio, medical testing, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2026 | $21M | $83M | Wondfo Biotech · BOC Capital · Changfa · IDG Capital | ↗ |
| SERIES A✓Equity / VC | May 2023 | $14M | $55M | IDG Capital · Wondfo Biotech · ISeed Capital · Sanmei Investment | ↗ |
Growth signals
Latest recorded traffic for Beijing Puyi Biotechnology is 220 monthly website visits, down 46.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Puyi Biotechnology in the Haidian ecosystem
The Beijing Puyi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Wondfo Biotech- SISanmei Investment
IDG Capital
ISeed Capital
Shuimu Venture Capital
BOC Capital
Changfa- GCGuoke Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Puyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Puyi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








